Purpose
Pulmonary arteriel hypertension (PAH) is one of the most important childhood health problem associated with significant morbidity and mortality. Despite improvements, best management of pediatric PAH is still unclear, especially secondary to congenital heart disease (CHD). The aim of our study was to assess the outcomes of various PAH targeted therapies in paediatric patients.
Methods
Functional status, six-minute walk test, mean BNP values, haemodynamic and echocardiographic data of 51 paediatric idiopathic PAH and PAH associated with CHD patients admitted between 2007 and 2014 were reviewed at diagnosis and at first year follow-up at our medical center. Patients were groupped according to first line therapy started as mono or combination of PAH spesific agents.
Methods
Functional status, six-minute walk test, mean BNP values, haemodynamic and echocardiographic data of 51 paediatric idiopathic PAH and PAH associated with CHD patients admitted between 2007 and 2014 were reviewed at diagnosis and at first year follow-up at our medical center. Patients were groupped according to first line therapy started as mono or combination of PAH spesific agents.
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
